Drug developed for lung disease may slow biological aging in surprising ‘bonus’

Rentosertib, a drug identified through artificial intelligence for idiopathic pulmonary fibrosis, showed a reduction in biological aging markers equivalent to three to four years in a clinical trial of patients with the lung disease.

Next story